Opko Health Inc (OPK) 9.26 $OPK OPKO Health Announces

New Post Public Reply Private Reply Replies (0) Message Board

Jun 14, 2016 at 7:17 AM

Opko Health Inc (OPK) 9.26 $OPK

OPKO Health Announces Move to NASDAQ Stock Market
BusinessWire - Mon Jun 13, 8:10AM CDT
OPKO Health, Inc. (NYSE:OPK) ("OPKO" or the "Company"

announces that it will move its stock exchange listing to The NASDAQ Stock Market from The New York Stock Exchange (the "NYSE"

. The Company expects its common stock will begin trading on the NASDAQ Global Select Market ("NASDAQ"

on June 24, 2016, and its shares will continue to trade under the ticker symbol "OPK."
OPK: 9.26 (-0.04)

Covered Call Alerts For Gilead Sciences, Western Digital, Costco, Opko Health and Ulta Salon Cosmetics & Fragrance Inc. Released By InvestorsObserver
PR Newswire - Wed Jun 08, 9:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GILD, WDC, COST, OPK and ULTA.
OPK: 9.26 (-0.04), GILD: 83.98 (-0.47), COST: 154.95 (+0.08), ULTA: 237.95 (-2.03), WDC: 46.28 (-0.57)

OPKO to Discuss Draft Coverage Determinations for 4Kscore(R) Test at 2016 Jefferies Healthcare Conference
BusinessWire - Tue Jun 07, 3:05PM CDT
OPKO Health, Inc. (NYSE: OPK) today announced that senior management will discuss recent draft local coverage determinations by certain Medicare Administrative Contractors for OPKO's 4Kscore(R) test at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2016 at 11:30 AM (EDT). OPKO previously announced that Novitas Solutions issued a positive draft local coverage determination proposing to establish reimbursement coverage for patients with PSA levels > 3 ng/mL who have not yet had a biopsy, or patients with a PSA level of > 3 ng/mL who have had at least one prior negative biopsy and are considered to be at higher risk. The draft coverage determination was subsequently retired by Novitas due to a potential conflict with another Medicare Administrative Contractor. Palmetto GBA had issued a draft non-coverage determination on May 27th for the 4Kscore test.
OPK: 9.26 (-0.04)

Biotechnology Stocks in Motion -- Celldex Therapeutics, Medivation, Opko Health, and ACADIA Pharma
PR Newswire - Tue Jun 07, 7:05AM CDT
On Monday, June 06, 2016, the NASDAQ Composite ended the trading session at 4,968.71, up 0.53%; the Dow Jones Industrial Average advanced 0.64% to finish at 17,920.33; and the S&P 500 closed at 2,109.41, up 0.49%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Celldex Therapeutics Inc. (NASDAQ: CLDX), Medivation Inc. (NASDAQ: MDVN), Opko Health Inc. (NYSE: OPK), and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). Learn more about these stocks by accessing their free trade alerts at:
MDVN: 60.03 (+0.02), ACAD: 38.10 (-1.50), OPK: 9.26 (-0.04), CLDX: 4.05 (-0.07)

OPKO Health to Present at the 2016 Jefferies Healthcare Conference
BusinessWire - Thu Jun 02, 7:47AM CDT
OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2016 at 11:30 AM (EDT).
OPK: 9.26 (-0.04)

OPKO Health Receives Proposed/Draft Medicare Local Coverage Determination for 4Kscore(R) Test
BusinessWire - Fri May 27, 7:30AM CDT
OPKO Health, Inc. (NYSE:OPK) ("OPKO" or the "Company"

announces that Novitas Solutions has issued a draft local coverage determination for the 4Kscore(R) Test, the only blood test that accurately identifies an individual patient's risk for high-grade, aggressive prostate cancer. Novitas Solutions is a Medicare Administrative Contractor (MAC) for Medicare jurisdictions L and H, with responsibility for nearly 10 million Medicare beneficiaries in New Jersey, Pennsylvania, Maryland, the District of Columbia and Texas, among other geographies.
OPK: 9.26 (-0.04)

Global Vitamin D Deficiency Disorders Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Merck, OPKO Health, DSM Biologics Holdings - Research and Markets
BusinessWire - Fri May 27, 6:57AM CDT
Research and Markets has announced the addition of the "Vitamin D Deficiency Disorders Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
OPK: 9.26 (-0.04), MRK: 56.11 (-0.70)

OPKO Health, Inc. - Product Pipeline Review - 2016 - Research and Markets
BusinessWire - Thu May 26, 4:36PM CDT
Research and Markets has announced the addition of the "OPKO Health, Inc. - Product Pipeline Review - 2016" company profile to their offering.
OPK: 9.26 (-0.04)

Under Armour trade offers a 19% return in 52 days, or find similar option trades on Opko Health, Herbalife, Costco, and Microsoft
PR Newswire - Wed May 25, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for UA, OPK, HLF, COST and MSFT.
UA: 37.45 (-0.93), HLF: 60.62 (-1.27), OPK: 9.26 (-0.04), COST: 154.95 (+0.08), MSFT: 50.14 (-1.34)

Cocrystal Pharma to Present at Jefferies 2016 Healthcare Conference
Marketwired - Wed May 25, 7:01AM CDT
Cocrystal CEO & CMO to Present Thursday, June 9, 2016, 8:30 AM ET in NYC
OPK: 9.26 (-0.04)

Learn how to target a 20% return on Google Inc, or get option-trade ideas on LinkedIn, Opko Health, Seagate Technology, and First Solar or any stock you choose
PR Newswire - Mon May 16, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GOOG, LNKD, OPK, STX and FSLR.
FSLR: 47.79 (-0.72), LNKD: 192.21 (+61.13), OPK: 9.26 (-0.04), STX: 22.68 (-0.46), GOOG: 718.36 (-1.05)

OPKO Announces Appointment of Douglass Laidlaw as Vice President of Medical Affairs
BusinessWire - Wed May 11, 7:30AM CDT
OPKO Health, Inc. (NYSE:OPK) today announced the appointment of Douglass Laidlaw, PhD as Vice President of Medical Affairs to support the anticipated launch of RAYALDEE(R).
OPK: 9.26 (-0.04)

Cocrystal Pharma Announces Filing 2016 First Quarter Financial Statements and Provides Company Update
Marketwired - Wed May 11, 6:30AM CDT
BOTHELL, WA and ATLANTA, GA--(Marketwired - May 11, 2016) - Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, today announced the filing of its financial statements for the quarter ending March 31, 2016 and provided an update on the Phase Ia/Ib clinical study of CC-31244.
OPK: 9.26 (-0.04)

OPKO Announces Appointment of Thomas Nusbickel as Senior Vice President of Pharmaceutical Marketing and Market Access
BusinessWire - Tue May 10, 7:30AM CDT
OPKO Health, Inc. (NYSE:OPK) today announced the appointment of Thomas Nusbickel as Senior Vice President of Pharmaceutical Marketing and Market Access to support the anticipated launch of RAYALDEE(R).
OPK: 9.26 (-0.04), AMGN: 153.08 (-1.70)

OPKO Health reports 1Q loss
Automated Insights - Mon May 09, 5:32PM CDT
MIAMI (AP) _ Opko Health Inc. (OPK) on Monday reported a loss of $12 million in its first quarter.
OPK: 9.26 (-0.04)

OPKO Health Reports First Quarter Financial and Operating Results
BusinessWire - Mon May 09, 3:13PM CDT
--Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and OPKO Health Entered into Agreement for OPKO's RAYALDEE(R); OPKO to Receive up to $282 Million in Upfront and Milestone Payments, Plus Tiered Double-Digit Royalties; Vifor Fresenius also Acquired an Option for Rights to the U.S. Dialysis Market for a New Dosage Form of RAYALDEE Which Provides for Payment to OPKO of up to $555 Million in Additional Milestone Payments Plus Double-Digit Royalties if Exercised
OPK: 9.26 (-0.04)

Big Insider Moves at Majesco, Phillip Frost Discloses Major Insider Transaction
ACCESSWIRE - Mon May 09, 10:09AM CDT
NEW YORK, NY / ACCESSWIRE / May 9, 2016 / After picking up a new management team and additional board of directors, stagnant video gaming firm Majesco Entertainment Co. (NASDAQ:COOL) just landed key insider investments totalling 9.9% of shares outstanding as of May 9. Leading the aggressive accumulation is the legendary biotechnology investor Dr. Phillip Frost, CEO of Opko Health (NYSE:OPK) and former CEO of generics giant Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA).
YHOO: 36.47 (-0.36), COOL: 0.82 (-0.06), OPK: 9.26 (-0.04), CDXC: 5.65 (+0.29), TEVA: 53.22 (+0.21), MJCO: 5.15 (-0.03)

SciVac Therapeutics and VBI Vaccines Announce Completion of Merger Transaction
GlobeNewswire - Mon May 09, 7:30AM CDT
-- SciVac Therapeutics changes its name to VBI Vaccines
OPK: 9.26 (-0.04), VBIV: 4.14 (-0.22)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Veterans Transitioning to Real Estate with Scholarships

Tapping Military Skills for Civilian Gain Finding a new career after military service is a mountain of a task, but veterans now have a golden ticket into the real estate appraisal world. The Appraisal Institute's Next Mission Scholarship is throwing veterans a $1,000 life preserver to dive into a field where their military-honed skills already shine. The Power of a...

Fluence Energy Faces Major Lawsuit Amid $3B Loss

Securities Class Action: A Storm Brewing Just when you think you've got a grip on the market, a sharp right hook can come out of nowhere. Fluence Energy (NASDAQ:FLNC) is dealing with one of those punches now, getting dragged into the courtroom over claims they fudged financial lines. They hail innovation in energy storage, but shareholders are left shaking in their boots...

Celebree Gains Franchise Momentum: A New Frontier

The Climb: Celebree Schools on the Rise Here's a nugget in the franchise world that's causing a stir: Celebree School is making moves up the Franchise Times Top 400. When we're talking about a hop, skip, and jump through 84 spots since 2023, you can't help but notice. It's the third year in a row they're climbing this ladder, and it's making ripples. Franchise Expansion...

Coventry's Jacobs Joins European Life Settlement Execs

Neal Jacobs Steps Up in Life Settlements Coventry has added another feather to its cap with Neal Jacobs, their Senior Managing Director of Capital Markets, joining the Executive Committee of the European Life Settlement Association (ELSA). Elected at ELSA's Annual General Meeting on September 15, 2026, Jacobs brings a wealth of experience that promises to bolster the...

OmniActive's Fenavari: A New Era in Women's Health

Pioneering Women's Health with Fenavari You ever wonder why some health products get all the hype? Here's one for the book: OmniActive Health Technologies launching Fenavari, their top-tier contender in the women's health market. Now, we're not talking your run-of-the-mill supplement here. We're stepping onto a new playing field, especially with Dr. Taz Bhatia stepping...

Omneky Outshines Competitors in AI Ad Scoring

Brewing a better ad with AI isn't just about the model you plug in—it's about the wizardry wrapping around it. Omneky's latest caper in the AI advertising game has snagged the spotlight, pulling a hearty 8.8 taste score on a recent TasteBench comparison. That's not a minor tweak, folks, but a whopping 1.2-point lead over the shadow-chasing curves of the next...

Think Tank Pushes for Bold Parkinson's Prevention Plan

A New Era for Parkinson's Disease Prevention The Parkinson's Foundation has rolled out its battle plan to take on Parkinson's disease from the ground up, shifting gears from managing symptoms to stopping the illness before it starts. It's about damn time, too. With the disease being the fastest-growing neurodegenerative disorder and impacting 10 million people worldwide,...

AtWork Welcomes Franchise Vet Sarah Goehring

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....

Quark Baby's Milk Warmer Debut at Vancouver & Dubai

An Unconventional Pitch for Baby Gear Quark Baby is strutting its stuff not just in Vancouver but all the way in Dubai. Yeah, we're talking about a milk warmer hitting two major expos. What's the deal with an award-winning brand from Vancouver making so much noise? From October 17-18, they're home-court at The Baby Show Vancouver, and by October 22-24, they're in Dubai at...

Special Needs Group Partners with MAST to Enhance Accessibility

Accessible Travel Takes the Spotlight Ah, the travel biz—just when you think you’ve got it all figured out, along comes a partnership like this to shake things up. Special Needs Group, the big cheese in mobility and medical equipment rentals, is teaming up with MAST Travel Network. Together, they're rolling out initiatives to make the world a bit more accessible, even...